Economic and Clinical Outcomes Assessment of Immuno-Oncology Agents: A Guide for Payer Decision Makers Web Activity

• Release Date: August 31, 2020
• Expiration Date: February 28, 2022
• Estimated Time to Complete Activity: 1.0 hour
• Compatible with all modern browsers and mobile devices

EXPERT FACULTY

Yung Lyou, MD, PhD                                    Oncologist Assistant Clinical Professor, Department of Medical Oncology City of Hope Click here for biography Edmund Pezalla, MD, MPH                                                       CEO  Enlightenment Bioconsult, LLC Click here for biography

TARGET AUDIENCE

• Managed medical directors, clinical pharmacists, specialty pharmacists, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations
• Pharmacy directors, registered nurses, case managers, policy administrators, utilization managers, C-suite executives, and IT professionals

STATEMENT OF NEED/PROGRAM OVERVIEW

The advent and rapid escalation of targeted cancer therapies has led to the emergence of sophisticated immuno-oncology agents. However, the historically high cost of these agents has compelled payers to initiate strategies to control utilization and manage costs. Because of the explosive growth of this category and their corresponding budgetary impact, healthcare decision makers (HCDMs) and managed care professionals require education on the principles of immuno-oncology and the mechanisms of action behind these novel treatments. Furthermore, given increased focus on value-based benefit design, utilization management, and payer-led clinical interventions to address shortfalls in oncology practice, managed care stakeholders also have a need for information to effectively address the evolving paradigm of cancer treatment. This symposium will provide HCDMs and managed care professionals with the required education on the principles of immuno-oncology and the mechanisms of action behind these novel treatments.

Educational Objectives 
At the conclusion of this activity, participants should be able to demonstrate improved ability to: 

1. Characterize the role of the immune system in immunosurveillance and elimination of malignant cell lines
2. Explain the mechanisms of action of novel immuno-oncology agents such as PD-1 and PD-L1 inhibitors and CAR-T therapies
3. Describe key outcomes measures in immuno-oncology and the importance of cumulative assessment of outcomes
4. Apply comprehensive analyses of emerging clinical trial data for checkpoint inhibitors and CAR-T therapies
5. Illustrate current and proposed payer initiatives for the funding and management of checkpoint inhibitors and CAR-T therapies

ACCREDITATION

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Impact Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour (0.10 CEU) of the Accreditation Council for Pharmacy Education.

Universal Activity Number: JA4008162-9999-20-2256-H01-P
Type of Activity: Application

Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy.  PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The PIM planners and managers have nothing to disclose.
The Impact Education, LLC® planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

METHOD OF PARTICIPATION AND REQUEST FOR CREDIT
There are no fees for participating and receiving CME/CE credit for this activity. During the period of accreditation participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) successfully complete the post-test with a score of 75% or better; 4) and complete the evaluation form. Upon completion of the full CME/CE activity, a certificate will be made available immediately to download and print.

For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account. Credit must be uploaded to CPE Monitor within 30 days.

MEDIA
Internet